Neurolixis
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
34145 Pacific Coast Hwy 504, Dana Point,...Phone Number
(949) 214-4017Website
www.neurolixis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Neurolixis
Neurolixis is an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for central nervous system disorders, including Parkinson's disease, rare autism spectrum disorders, and depression. The company is developing innovative compounds such as NLX-112 for movement disorders and NLX-101 for Rett syndrome. Neurolixis aims to address unmet medical needs in psychiatric and neurological conditions through its promising pipeline of clinical and preclinical assets. Founded by experienced professionals in the pharmaceutical industry, Neurolixis is committed to advancing treatments that improve patient outcomes.Explore more
Neurolixis Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurolixis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Neurolixis had a recent Job posting/layoffs
Check out if Neurolixis is spiking on competitors!
Earning: See what the market has to say on Neurolixis recently announced quarterly report
Funding: Get notified immidiatlly once Neurolixis has new funding data
Congratulate Masked Content for being promoted to Masked Content at Neurolixis
Check if Neurolixis has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Neurolixis launches new products
Website visits: Recent activity has been detected on your website
Neurolixis, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Neurolixis as Masked Content
Find 3 more new buyers
Compare Similar Companies to Neurolixis
Compare insights from companies similar to Neurolixis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Neurolixis
<$5M
1-10
Private
-
2011
Mark KlevenSenior Vice President, Scientific Operations, Chief Operating Officer
Company Profile Activity
Activity Insights
Neurolixis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neurolixis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neurolixis.
Neurolixis Tech Stack
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
Neurolixis News & Media
Neurolixis Secures Orphan Medicinal Product Designation for NLX-112 as a Treatment for Spinocerebellar Ataxia
European Commission approves OMP Designation for NLX-112 (befiradol) following compelling results in studies funded by the US Dept of Defense. CASTRES, FRANCE, September 25, 2024 /EINPresswire.com/ -- Neurolixis Inc., a biopharmaceutical company …Dual Clinical Efficacy of NLX-112 in Parkinson’s Disease Presented at Scientific Meetings
Ground-breaking Non-Dopaminergic Drug Combining Both Anti-Dyskinetic and Anti-Parkinsonian Properties NJ, USA, August 22, 2023 /EINPresswire.com/ -- Neurolixis, Inc., a private, clinical-stage company developing innovative drug therapies for the …Neurolixis to present results of successful NLX-112 proof-of-concept clinical trial at the World Parkinson’s Congress
A First-in-Class Highly Selective and Efficacious Serotonin 5-HT1A Receptor Agonist for treatment of Parkinson’s Disease PARK RIDGE, NJ, UNITED STATES, June 27, 2023 /EINPresswire.com/ -- Neurolixis, Inc., a private, clinical-stage company developing …Neurolixis Announces Positive Ph2A Proof-of-Concept on NLX-112 in Levodopa-Induced Dyskinesia in Parkinson’s Disease
A New Approach Using a First-in-Class Highly Selective and Efficacious Serotonin 5-HT1A Receptor Biased Agonist NJ, UNITED STATES, March 20, 2023 /EINPresswire.com/ -- Neurolixis, Inc., a private, clinical-stage company developing innovative drug …
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neurolixis
Sign Up For FreeTo access detailed company insights
Neurolixis is an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for central nervous system disorders, including Parkinson's disease, rare autism spectrum disorders, and depression. The company is developing innovative compounds such as NLX-112 for movement disorders and NLX-101 for Rett syndrome. Neuro... Read More
